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Available online 3 May 2016Background: Atrial ﬁbrillation (AF) patients eligible for cardioversion tend to be younger and are at lower risk
than ‘general’ AF clinic populations. We evaluated the incidence of major bleeding and death, as well as the pre-
dictive value of the HAS-BLED score in non-valvular AF patients who underwent electrical cardioversion (ECV).
Methods: Consecutive non-valvular AF patientswhounderwent ECVwere recruited.Major bleeding episodes and
mortality were recorded. Factors associated with both endpoints and the predictive value of the HAS-BLED score
were analysed.
Results: 406 patients (281males; age 66.9± 10.9 years) undergoing 571 ECVwere included. After a follow-up of
nearly 3 years, 20 patients presented with major bleeding (1.9%/year;) and 26 patients died (2.4%/year). The
HAS-BLED score predicted both major bleeding [c-statistics: 0.77; 95%CI: 0.71–0.83; p b 0.001] and mortality
[c-statistics: 0.83; 95%CI: 0.79–0.87; p b 0.001]. Variables associated with bleeding were: renal impairment
(HR: 4.35; 95%CI: 1.22–15.52; p = 0.02), poor quality anticoagulation (HR: 3.21; 95%CI: 1.11–9.32; p = 0.03),
previous bleeding-predisposition (HR: 5.43; 95%CI: 1.76–16.75; p = 0.003) and the HAS-BLED score (HR:
1.88; 95%CI: 1.34–2.64; p b 0.001). Factors associated with mortality were: age (HR: 1.08; 95%CI: 1.03–1.14;
p = 0.004), poor quality anticoagulation (HR: 3.11; 95%CI: 1.15–8.36; p = 0.02), previous bleeding-
predisposition (HR: 5.90; 95%CI: 1.41–24.65; p = 0.01), liver impairment (HR: 9.27; 95%CI:1.64–52.34; p =
0.01), the CHA2DS2-VASc score (HR: 1.63; 95%CI: 1.18–2.26; p = 0.003) and the HAS-BLED score (HR: 2.74;
95%CI: 1.86–4.04); p b 0.001).
Conclusions: In AF patients undergoing ECV, major bleeding episodes and mortality were independently
associated with poor quality anticoagulation control and previous bleeding-predisposition. The HAS-BLED
score successfully predicted major bleeding and mortality.
© 2016 Elsevier Ireland Ltd. All rights reserved.Keywords:
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.1. Introduction
Thromboprophylaxis with oral anticoagulation (OAC) in atrial
ﬁbrillation (AF) is highly effective in preventing ischaemic stroke and
mortality, however it increases the risk of bleeding complications, the
most serious of which is intracranial haemorrhage [1].
Among AF patients, those who undergo a rhythm control strategy
tend to be younger and have less comorbidities [2–5] Electrical
cardioversion (ECV) is commonly used to restore sinus rhythm in AF;
however, nearly half of the individuals have arrhythmia recurrence in
the ﬁrst few months after the procedure [6]. International guidelines
recommend long-term anticoagulation regardless of procedural success
based on thromboembolic risk [7,8].
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bleeding risk in AF patients taking OAC [9,10]. Among these, the HAS-
BLED score [11] performs better than other schemes for predicting
serious bleeding in cohorts of AF patients taking vitamin K antagonists
(VKA) and non-VKA. Importantly, the HAS-BLED is the only score able
to predict intracranial haemorrhage in AF [11]. Guidelines recommend
the use of the HAS-BLED score to assess the risk of major bleeding in
AF patients, and draw attention to revisable bleeding risk factors [7,8].
However the HAS-BLED score has not been explored in AF patients
who undergo ECV.
The aims of the present study are as follows: 1) to analyse the
incidence of short and long-term major haemorrhagic complications
and mortality in AF patients who undergo ECV; 2) to study factors
associated with these adverse events; and 3) to assess the predictive
value of the HAS-BLED score for long-term bleeding and mortality in
anticoagulated AF patients undergoing ECV.2. Methods
2.1. Study patients and data collection
We recruited all consecutive patients with persistent, non-valvular
AF who had undergone one or more elective ECV procedures between
January 2008 and July 2012 in a University Hospital in South-eastern
Spain. Patients with valvular-AF (rheumatic valve disease, severe valve
disease, prosthetic valve or mitral valve repair surgery) were excluded.
Data on baseline clinical characteristics, risk factors for bleeding and
antithrombotic drug treatment were obtained from the hospital
medical records. The CHA2DS2-VASc (congestive heart failure,
hypertension, age ≥ 75, diabetesmellitus, prior stroke or transient ische-
mic attack, vascular disease, age 65–74, female sex) and the HAS-BLED
(hypertension, abnormal renal/liver function, previous stroke, previous
bleeding/predisposition, labile INR, age ≥ 65, concomitant drugs or alco-
hol abuse) scores were calculated for every patient using established
deﬁnitions of the different risk factors, as previously described [11,12].
We considered lone AF as the absence of heart disease, hypertension,
diabetes, pulmonary, renal or thyroid disease and those situations
which could precipitate the arrhythmia, such as surgery or alcohol
consumption.Hypercholesterolemiawas deﬁned as low-density lipopro-
tein cholesterol N130 mg/dl or actual lipid-lowering therapy. Patients
with asthma, chronic obstructive pulmonary disease or obstructive
sleep apnea were classiﬁed as having pulmonary disease. Thyroid disease
was deﬁned as hypo or hyperthyroidism or treatment for either
pathology.
Following international recommendations, anticoagulant therapy
was maintained for at least 4 weeks after ECV in most of the patients,
but the decision about the continuation of anticoagulation after the
procedure was at the discretion of the responsible physician. Patients
with different types of anticoagulant treatment were included.
Acenocoumarol is the most widely used VKA in Spain and most of the
individuals received this therapy. As non-VKA oral anticoagulants
(NOAC) were ﬁrst approved in Spain in 2011, only a small number of
individuals received these drugs when this study was conducted.
In patients who received VKAs, data about quality of anticoagulation
control after ECVwere collected. The time in therapeutic range (TTR)was
calculated as the percentage of tests in range (international normalized
ratio (INR): 2.0–3.0) over total number of tests (over a maintenance
period of at least six consecutive months). An average TTR b60% was
considered as poor quality anticoagulation control (labile INR).
In our region, all citizens have a personal identiﬁcation number that
enables healthcare professionals to consult data about all hospital
admissions, visits to the out-patient clinics, deaths, as well as data
about medical prescriptions and other clinical information related to
the patients.We recordedmajor bleeding episodes and deaths occurred
after every ECV. Data on stroke and other thromboembolic events (TE)in this population were also registered and have been published
elsewhere [13].
Success of ECV and recurrence rates (symptomatic or asymptomatic
AF, conﬁrmed by a physician) were also registered. Follow-up started
the day of the inclusion (day when the ECV was performed) and
ended on July 2013.
Major bleedingwas deﬁned following the 2005 International Society
of Thrombosis and Haemostasis criteria [14]. All deaths had to be
conﬁrmed by the medical records. Mortality was classiﬁed as being of
vascular (cardiac, stroke, pulmonary embolism etc.) or non-vascular
(neoplasm, trauma, respiratory disease etc.) origin.2.2. Statistical analysis
Categorical variables were expressed as percentages. The
Kolmogorov–Smirnov test was used to analyse the normal distribution
of continuous variables. Quantitative variables are expressed as
mean ± standard deviation or as median (interquartile range (IQR)),
depending on its distribution being normal or not. In order to assess
the association between the different individual risk factors and the
incidence of an adverse event, univariate Cox-regression models and
multivariate models were ﬁtted. All factors identiﬁed from the
univariate analyses with a p value b0.10 were used in the multivariate
analysis. We also evaluated the impact of the CHA2DS2-VASc and the
HAS-BLED scores with a Cox-regression model. For the multivariate
analysis, the scores were evaluated separately, using the score as a
dependent variable and keeping in the model only other variables
with a p value b0.01 in the univariate analysis that are not included in
the score. The ability of HAS-BLED score to predict major bleeding and
mortality was calculated with the area under receiver operating
characteristic (ROC) curve and the c-statistic. Data analysis was
performed using SPSS, version 20.0 for Windows (SPSS Inc., Chicago,
IL). A p value b 0.05 was considered as signiﬁcant.2.3. Ethics
This study was approved by the Ethical Committee of Alicante
University Hospital (approval number: PI_2013/09) andwas performed
in accordance with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments. Patients gave their
informed consent prior to their inclusion in the study.3. Results
3.1. Baseline characteristics and anticoagulation after cardioversion
We included 406 patients, who underwent 571 ECV. Baseline char-
acteristics of the patients are shown in Table 1. Table 2 shows success
of ECV, AF recurrence rates and use of OAC after cardioversion. After 4
procedures (0.7%), the responsible physician did not prescribe OAC as
the arrhythmia duration was b48 h and the patients had no risk factors
for embolism. NOAC (dabigatran or rivaroxaban) were used at some
time during follow-up after 86 procedures (15.1%), although the rate
of overall use around the time of ECV was low (6.2%), as shown in
Table 2.
Over the follow-up period, anticoagulant therapy was stopped after
63 ECV (11.1%). Of these, themain reason for cessation of OACwas cited
as a return to sinus rhythm (39 patients; 62.0%). Median time to
anticoagulation withdrawal was 368 (202–367) days.
Among patients on VKAs, data on INR control during follow-up for at
least 6 consecutive months were not available after 29 procedures
(5.4%). For the remainder of ECV patients, mean TTR was 58.91 ±
14.91%, with TTR b60% in 215 (39.7%).
Table 1
Baseline characteristics of 406 patients with non-valvular atrial ﬁbrillation undergoing
electrical cardioversion.
Patients Mean ± SD median
(IQR) n (%)
Age (years) 66.9 ± 10.9
Male sex 281 (69.2)
Isolated AF 37 (9.1)
Hypertension 324 (80.0)
Heart failure 110 (27.2)
Diabetes mellitus 117 (28.9)
Previous embolism 23 (5.7)
Vascular disease 90 (22.2)
Actual or previous tobacco use 186 (51.0)
Hypercholesterolemia 273 (68.3)
Pulmonary disease 118 (29.1)
Thyroid disease 41 (10.1)
Previous bleeding/bleeding predisposition (anaemia) 79 (19.4)
Renal impairment 20 (4.9)
Liver impairment 3 (0.7)
Concomitant drugs* 67 (16.5)
Alcohol abuse 28 (6.9)
CHA2DS2-VASc score**:
Low risk
Moderate/intermediate risk
High risk
3 (2–4)
35 (8.6)
60 (14.8)
311 (76.6)
HAS-BLED score***:
Low risk
Moderate/intermediate risk
High risk
2 (1–3)
110 (28.7)
104 (27.1)
170 (44.2)
Abbreviations: AF: atrial ﬁbrillation.
*Antiplatelet agents, non-steroidal anti-inﬂammatory drugs.
CHA2DS2-VASc: congestive heart failure (1 point), hypertension (1 point), age ≥ 75 (2
points), diabetes mellitus (1 point), prior stroke or transient ischemic attack (2 points),
vascular disease (1 point), age 65–74 (1 point), female (1 point).
**Low risk:males with 0 points, females with1 point;moderate/intermediate risk:males with
1 point; high risk: ≥2 points.
HAS-BLED: hypertension (1 point), abnormal renal/liver function (1 point each), previous
stroke (1 point), previous bleeding/predisposition (1 point), labile INR (1 point), age ≥ 65
(1 point), concomitant drugs or alcohol abuse (1 point each).
***Low risk: 0–1 points;moderate/intermediate risk: 2 points; high risk: ≥3 points.
Table 3
Major bleeding events, mortality and thromboembolic events during follow-up.
Major
bleeding
Death Thromboembolism
Number of patients 21 26 20
Annual incidence (%) 1.9 2.4 1.9
Total number of events 23 26 28
Time to ﬁrst event
(days)*
672 (207–963) 664 (354–1252) 746 (149–1180)
Age (years)** 70.1 ± 9.5 74.6 ± 7.6 73.7 ± 13.0
Male sex*** 17 (85.0) 22 (84.6) 12 (60.0)
CHA2DS2-VASc score* 4 (2–5) 4 (2–6) 4 (3–6)
HAS-BLED score* 4 (2–6) 4(3–6) 4 (3–5)
*Median (interquartile range).
**Mean ± SD.
***N (%).
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Median follow-up was approximately 3 years [1005 (619–1489)
days], during which 30 patients (7.3%) were lost to follow-up.
Table 3 summarises the observed adverse events. Two patients
presentedwithmore than one bleeding event, with 23 the total number
of episodes. Bleeding sites were as follows: 12 gastrointestinal (52.3%),
5 neurological (21.7%), 4 urinary tract (17.4%) and 2 had other origins
(8.6%). The annual incidence of intracranial haemorrhage was 0.4%. Of
the bleeding events, 4 (17.4%) were the cause of death (3 intracranial
and 1 gastrointestinal). Mortality of intracranial bleeding was 60%. All
patients were receiving anticoagulant therapy at point of the bleeding
event: 22 (95.7%) with acenocoumarol and 1 (4.3%) with dabigatran.
Concomitant antiplatelet therapy was prescribed in 7 (30.4%). After
the bleeding episode, anticoagulant therapy was stopped in 3 patients
(13.0%) and antiplatelet therapy in another 3 (13.0%). As shown in
Table 3, median time to major bleeding was almost 2 years. Only 2Table 2
Cardioversion success, atrialﬁbrillation recurrence rates and anticoagulant ther-
apy after 571 electrical cardioversion procedures.
n (%)
ECV success 495 (87)
AF recurrence 399 (80.6)
Anticoagulant therapy after ECV:
Acenocoumarol
Non-vitamin K antagonists
Warfarin
567 (99.3)
519 (91.6)
35 (6.2)
13 (2.2)
Abbreviations: ECV: electrical cardioversion; AF: atrial ﬁbrillation.episodes occurred in the ﬁrst 30 days after ECV, both patients were on
acenocoumarol.
Causes of death were as follows: (i) vascular: 14 (54.0%): i.e. heart
failure: 4; haemorrhagic stroke: 3; sudden death: 3; ischaemic stroke:
2; gastrointestinal bleeding: 1; aortic aneurism rupture: 1; (ii) non-
vascular: 10 (38.0%): i.e. neoplasm: 8; infection: 2; and (iii) unknown:
2 (8.0%). Twenty-three (88.5%) patients who died were receiving
anticoagulants: 21 acenocoumarol, 1warfarin and 1 dabigatran.Median
time to death was approximately 2 years and no patient died in the ﬁrst
month after ECV.
During follow-up, 20patients experienced 28TE, beingmost of them
(n= 25; 96.1%) strokes or transient ischaemic attacks. Only one TEwas
considered to be related to the procedure, occurring 48 h after ECV in a
female patient on acenocoumarol. All patients (n = 20, 100.0%) who
sustained TE had received acenocoumarol after the ECV. As previously
mentioned, details about stroke and thromboembolism in this
population have been published elsewhere [13].
3.3. Predictors of major bleeding and death
ROC-curves analysis showed that the HAS-BLED score was associat-
ed with major bleeding [c-statistic: 0.77; 95%CI: 0.71–0.83; p b 0.001]
and mortality [c-statistic: 0.83; 95%CI: 0.79–0.87; p b 0.001] (Fig. 1).
Fig. 2 shows the annual incidence of major bleeding and mortality,
based on HAS-BLED score.
Table 4 summarises determinants of major bleeding in the Cox
regression model. On multivariate analysis, factors independently
associated with bleeding were: renal impairment (HR: 4.35; 95%CI:
1.22–15.52; p = 0.02), poor quality anticoagulation control (HR: 3.21;
95%CI: 1.11–9.32; p = 0.03), previous bleeding or predisposition (HR:
5.43; 95%CI: 1.76–16.75; p = 0.003) and the HAS-BLED score (HR:
1.88; 95%CI: 1.34–2.64; p b 0.001).
Independent predictors of mortality on Cox-regression analysis
were: age (HR: 1.08; 95%CI: 1.03–1.14; p = 0.004), poor quality
anticoagulation (HR: 3.11; 95%CI: 1.15–8.36; p = 0.02), previous
bleeding or predisposition (HR: 5.90; 95%CI: 1.41–24.65; p = 0.01),
liver impairment (HR: 9.27; 95%CI:1.64–52.34; p = 0.01), the
CHA2DS2-VASc score (HR: 1.63; 95%CI: 1.18–2.26; p = 0.003) and the
HAS-BLED score (HR: 2.74; 95%CI: 1.86–4.04); p b 0.001) [Table 5].
4. Discussion
In this study, in a contemporary cohort of patients with non-valvular
AFwhounderwent ECV,we show for theﬁrst time that long-termmajor
bleeding and mortality were independently related to the HAS-BLED
score. The annual incidence of major haemorrhagewas 1.9% and annual
mortality was 2.4%. Second, quality of anticoagulation control in those
who continued on VKA after cardioversion was suboptimal (mean TTR
was 58.9%). Third, we show that independent predictors ofmajor bleed-
ing in these patients were: severe renal disease, poor quality
Fig. 1. ROC curves for the HAS-BLED score as a predictor of A) major bleeding and B) mortality.
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Fig. 2. Annual incidence of major bleeding and mortality depending on HAS-BLED category*. *Low risk: 0–1 points; moderate/intermediate risk: 2 points; high risk: ≥3 points.
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independent predictors of mortality were: advanced age, liver impair-
ment, suboptimal anticoagulation control and previous bleeding or
anaemia.
Observational data about bleeding complications and death in the
group of AF patients in which ECV is performed are scarce and, to the
best of our knowledge, the use of major bleeding risk scores has not
been previously validated in this setting. Our group has recently
described the incidence and predictors of ischaemic stroke and other
thromboembolic complications in this particular group of AF patients
[13]. A recent paper from the FibStroke study analysed postcardioversion
strokes (ischaemic strokes and intracranial bleeding), however risk
scores were not examined [15]. In our opinion, AF individuals who un-
dergo ECVdiffer from the “general”AF clinic populations, as, for example,
our patients are younger and have lower thromboembolic risk than
those patients with long-standing-persistent or permanent AF included
in the EORP-AF registry, study that describes contemporary AF manage-
ment by European cardiologists [4,5].
As previously shown [16], the incidence of adverse events peri-
cardioversion under the use of anticoagulant therapy — either with
VKAs or NOACs — is small. In the group analysed, only two major
bleeding episodes and one embolic stroke took place in the ﬁrst
month after ECV. All these patients were receiving acenocoumarol
as anticoagulant treatment. At long-term follow-up, most of theTable 4
Risk factors associated with major bleeding using Cox regression model.
Risk factor Univariate analysis HR (9
Age 1.03 (0.98–1.07); 0.22
Male sex 2.74 (0.80–9.32); 0.11
Hypertension 0.74 (0.27–2.00); 0.55
Heart failure 2.29 (0.97–5.39); 0.058
Diabetes 2.81 (1.19–6.61); 0.018
Previous embolism 0.04 (0.00–233.41); 0.48
Vascular disease 3.23 (1.37–7.60); 0.007
Actual or previous tobacco use 2.72 (1.05–7.00); 0.03
Previous bleeding or predisposition 9.21 (3.72–22.83); b0001
Renal impairment 15.09 (6.35–35.87); b0.0
Liver impairment 6.87 (0.91–5.59); 0.06
INR lability 4.17 (1.52–11.48); 0.006
Concomitant drugs* 2.91 (1.21–7.04); 0.01
Alcohol abuse 4.42 (1.62–12.07); 0.004
CHA2DS2-VASc score 1.20 (0.53–1.95); 0.15
HAS-BLED score 2.03 (1.53–2.68); b0.001
Abbreviations: INR: international normalized ratio.
*Antiplatelet agents, nonsteroidal antiinﬂamatory drugs.
** Onmultivariate analysis, the impact of the HAS-BLED scorewas analysed separately, using th
variate model that are already included in the score (previous bleeding or predisposition, renaadverse events occurred in patients under VKAs, and only two pa-
tients on NOACs (dabigatran) experienced bleeding or death. No TE
occurred in individuals on NOACs. Recently, Coquard and colleagues
[17] published their experience on 50 patients who underwent ECV
under anticoagulation with dabigatran and rivaroxaban. They
found that the use of NOACs for ECV is safe, with only one major
bleeding in a patient on rivaroxaban and no evidence of stroke. Our
data support the safety of the use of NOACs for cardioversion, never-
theless we need to highlight that the rate of use of this
anticoagulation therapy for ECV in our study was low.
The incidences of major bleeding and intracranial haemorrhage in
the patients studied (1.9% per year and 0.4% per year, respectively-
most received acenocoumarol as anticoagulant therapy) were broadly
similar to that reported with warfarin [18]. In concordance with other
studies [19], the mortality associated with bleeding episodes was high
(nearly 20%), particularly that of intracranial haemorrhage. Overall an-
nual mortality rate was 2.4%, with most of the deaths being of vascular
origin, and a signiﬁcant proportion of deaths related to intracranial or
gastrointestinal bleeds. In a substudy of the RELY (Randomized Evalua-
tion of Long-Term Anticoagulation Therapy) [20], which investigated
causes and predictors of mortality in AF patients taking oral
anticoagulation with dabigatran or warfarin, the annual death rate
was 3.8%. As expected,most deathswere of cardiovascular origin,whilst
more than one third were non-cardiovascular.5%CI); p value Multivariate analysis HR (95%CI); p value
0.73 (0.24–2.25); 0.59
2.88 (1.01–8.18); 0.05
0.79 (0.23–2.69); 0.71
2.64 (0.91–7.70); 0.08
5.43 (1.76–16.75); 0.003
01 4.35 (1.22–15.52); 0.02
3.08 (0.29–32.29); 0.35
3.21 (1.11–9.32); 0.03
0.81 (0.22–3.02); 0.75
2.57 (0.82–8.19); 0.11
1.88 (1.34–2.64); b0.001**
e score as a dependent variable, and excluding those factors with a p value b0.1 in the uni-
l impairment, liver impairment, INR lability, concomitant drugs and alcohol abuse).
Table 5
Risk factors associated with mortality in the Cox regression model.
Risk factor Univariate analysis HR (CI95%); p value Multivariate analysis HR (CI95%); p value
Age 1.09 (1.05–1.41); b0.001 1.08 (1.03–1.14); 0.004
Male sex 2.58 (0.89–7.50); 0.08 0.39 (0.12–1.22); 0.11
Hypertension 5.93 (0.80–43.81); 0.08 2.18 (0.27–17.73); 0.47
Heart failure 2.10 (0.97–4.55); 0.06 1.04 (0.44–2.48); 0.93
Diabetes 1.88 (0.87–4.11); 0.11
Previous embolism 3.55 (1.21–10.41); 0.02 2.93 (0.86–10.03); 0.09
Vascular disease 3.06 (1.42–6.62); 0.004 0.98 (0.37–2.58); 0.96
Actual or previous tobacco use 1.83 (0.83–4.03); 0.14
Previous bleeding or predisposition 5.85 (2.70–12.68); b0.001 5.90 (1.41–24.65); 0.01
Renal impairment 6.62 (2.66–16.52); b0001 1.25 (0.37–4.24); 0.71
Liver impairment 26.07 (3.70–69.90); b0.001 9.27 (1.64–52.34); 0.01
INR lability 2.99 (1.20–7.39); 0,01 3.11 (1.15–8.36); 0.02
Concomitant drugs* 1.91 (0.83–.40); 0.13
Alcohol abuse 2.56 (0.88–7.45); 0.08 1.85 (0.50–6.90); 0.35
CHA2DS2-VASc score** 1.58 (1.25–2.00); b0.001 1.63 (1.18–2.26); 0.003
HAS-BLED score** 2.37 (1.79–3.13); b0.001 2.74 (1.86–4.04); b0.001
Abbreviations: INR: international normalized ratio.
*Antiplatelet agents, non-steroidal anti-inﬂammatory drugs.
**On multivariate analysis, the impact of the CHA2DS2-VASc and HAS-BLED scores was analysed separately, using the score as a dependent variable, and excluding those factors with a p
value b0.1 in the univariate model that are already included in the score (age, sex, hypertension, heart failure, previous embolism and vascular disease for CHA2DS2-VASc and age, hyper-
tension, previous embolism, previous bleeding or predisposition, renal impairment, liver impairment, INR lability and alcohol abuse for HAS-BLED).
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procedure, however, an important ﬁnding of this study is that the qual-
ity of anticoagulation control in these real-world AFpatientswas subop-
timal. Acenocoumarol is the vitamin-K antagonistmost commonly used
in Spain and, even if the studies comparing its efﬁcacywith that of war-
farin are scarce, acenocoumarol has a higher risk of supratherapeuthic
INR, potentially leading to a poorer TTR [21]. A recent European Society
of Cardiology position document [22] recommended that AF patients
with risk factors for thromboembolism should receive effective antico-
agulant therapy by achieving a TTR N 70% when VKAs are used. None-
theless, nearly 40% of our patients had TTR b 60%, and mean TTR was
59%. Indeed, VanWalraven et al. [23] found that patients taking warfa-
rin generally spend more than a third of their time outside of the ther-
apeutic range and a recent Spanish multicentre observational study
[24] showed that AF patients on VKAs spend less than half of the time
within therapeutic range. Of note, the TTR, as an estimate the quality
of anticoagulation control, is a consistent bleeding risk marker [25]. In
our study labile INR tripled the risk of having serious bleeding complica-
tions and death.
To predict which AF patients are likely to do well on VKA (good av-
erage TTR), Apostolakis et al. [26] recently proposed and validated the
SAMe-TT2R2 score, which includes factors such as female sex, young
age, some medical conditions, rhythm control strategy, tobacco use
and race as predictors of poor anticoagulation control. The SAMe-
TT2R2 score has also been validated in different Spanish cohorts of pa-
tients on acenocoumarol, showing that a high SAMe-TT2R2 score (≥2)
translates into poorer quality of anticoagulation, with higher incidence
of cardiovascular events, bleeding and mortality [27]. The present
study is consistentwith these data, given that poor anticoagulation con-
trol carries a substantially higher risk of bleeding and death. In a retro-
spective study by Morgan and co-workers [28], which analysed stroke
incidence andmortality related to INR control inmore than 2000 AF pa-
tients taking warfarin, mortality rates were signiﬁcantly related to TTR.
Indeed, greater efforts should be made on improving anticoagulation
control, and a well-organized management of anticoagulant therapy
(for example in anticoagulation clinics) results in a higher proportion
of individuals with adequate anticoagulation levels [23]. We also pre-
sume that patients on VKA with inadequate TTR (despite good compli-
ance and clinical management) and those who are likely to have poor
anticoagulation control on VKA should be considered for treatment
with a NOAC.
Severe renal disease was another risk factor associated with major
bleeding, consistent with several studies. Our group has previouslyshown that renal insufﬁciency doubles bleeding risk in anticoagulated
AF patients [29]. In a post-hoc analysis of the AMADEUS study, moderate
to severe renal impairment increased bleeding risk in 60% and doubled
the risk of ischemic stroke [30]. However, the prevalence of AF in ad-
vanced stages of renal disease is high, affecting more than 25% of
haemodialysis patients [31]. Special care should be takenwhen deciding
about anticoagulant therapy in these patients, delicately balancing em-
bolic versus haemorrhagic risk.
In our study, previous bleeding and conditions that increased bleed-
ing risk (mainly anaemia) conferred a ﬁve-fold risk of having a major
bleeding event and increased mortality by 6-fold. Both prior bleeding
history or predisposition have been previously associatedwith bleeding
and death in AF patients [32].
The bleeding risk factors discussed above are components of the
HAS-BLED score, a simple, user-friendly, score, which was designed to
predict the risk of major bleeding in AF patients [11]. Our group has
demonstrated that the HAS-BLED risk score is associated to major
bleeding, cardiovascular events and mortality in AF patients taking
oral anticoagulation with acenocoumarol [29]. We now extend our pre-
vious study by showing that in AF patients undergoing ECV, most of
which continue with oral anticoagulation after the procedure, the
HAS-BLED score successfully predicted both long-term major bleeding
and mortality. Of note, an increase in one point with the HAS-BLED
score doubled the risk of major bleeding and tripled the risk of death,
with most of the bleeding episodes and nearly all deaths occurring in
patients with a high HAS-BLED score (≥3 points). Moreover, the HAS-
BLED score has a good predictive accuracy for both adverse events (c-
statistics N0.75). We previously reported that the HAS-BLED score had
a c-statistic for bleeding of 0.70 and of 0.62 for all-cause mortality in
AF patients taking acenocoumarol [29]. In the present study, we conﬁrm
that the HAS-BLED score is also a good predictor of mortality in non-
valvular AF patients. To our knowledge, this is the ﬁrst time that the
score is validated formajor bleeding andmortality in the particular pop-
ulation of non-valvular AF patients eligible for ECV.4.1. Limitations
Our study is limited by its single-centre cohort and observational de-
sign. Nonetheless it reﬂects a ‘real world’ situation. For these reasons,
and even if our study reports extensive and reliable data, some of the in-
formation may have been missed. Even if the number of events is rela-
tively low, it is in accordance with that of previous studies, and
48 A. García-Fernández et al. / International Journal of Cardiology 217 (2016) 42–48practically all the major bleeding complications and deaths could be
registered.
Anticoagulation therapy for cardioversion and during follow-upwas
not the same for all the patients, most of them received VKAs and a
smaller proportion took NOACs (dabigatran or rivaroxaban), for this
reason, a comparison between both anticoagulant therapies cannot be
made. The majority of the patients received acenocoumarol, a VKA
which is the one most commonly used in Mediterranean countries.
Although no studies have compared acenocoumarol and warfarin, the
former is believed to lead to less stable anticoagulation. TTR was
calculated as the proportion of tests in range. Although some would
conﬁne TTR to the Rosendaal method, measurement of the percentage
of tests in therapeutic range is a validated method, accepted in current
guidelines to estimate quality of anticoagulation for patients on VKAs
[7,33].
Another limitation of this study is that theHAS-BLED score could not
be calculated for every patient (because incomplete data about INR
were available); nevertheless the proportion of missing TTR data was
small.
5. Conclusion
In AF patients undergoing ECV long-term major bleeding episodes
and mortality were independently associated with poor quality
anticoagulation control and previous bleeding or predisposition. The
HAS-BLED score was signiﬁcantly associated with major bleeding and
mortality in these patients.
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